0UGB Stock Chart & Stats
C$12.74
C$0.00(0.00%)
At close: 4:00 PM EDT
C$12.74
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$10.23 - C$12.74
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
C$7.54M
Enterprise Value-C$1.80
Total Cash (Recent Filing)C$5.01M
Total Debt (Recent Filing)C$2.02M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.42
Shares Outstanding1,061,386
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA low debt-to-equity (~0.13) is a durable balance-sheet advantage: it reduces interest burden and gives the company financing flexibility during prolonged development cycles typical in pharma. This structural conservatism supports runway and strategic optionality despite operating losses.
Top-line MomentumImproving trailing revenue (TTM growth ~6.3%) indicates market traction or advancing programs. Sustainable top-line momentum, if maintained, can underpin future operating leverage and reduce reliance on external capital over several quarters, making revenue the core path to durability.
Lean Operating StructureA very small headcount (28 employees) signals a lean cost base and focused R&D/operations model. Lower fixed payroll and overhead can extend cash runway, allow targeted investment in key programs, and make scaling less capital intensive over the medium term.
Bears Say
Severe Profitability WeaknessExtremely negative margins show the core business is not generating returns: operating losses at this scale require material improvement in revenue efficiency or cost structure. Persistent deep losses threaten long-term viability absent durable margin recovery or new funding.
Persistent Cash BurnOngoing negative operating and free cash flow indicate consistent cash outflows that will deplete resources without external capital. This structural burn constrains strategic options, increases financing needs, and raises dilution risk unless operating performance meaningfully improves.
Equity Volatility & Financing RiskVolatile equity and prior capital changes signal a pattern of financing that may recur given losses. With weak profitability and cash burn, the company faces durable dilution and capital-raising risk, which can impair shareholder value and limit long-term strategic flexibility.
COSCIENS Biopharma News
0UGB FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest share price was C$10.23 and its highest was C$12.74 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$7.54M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Aug 13, 2026 which is in 9 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on May 12, 2026. The company reported -C$0.702 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 1,061,386 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.702 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in GB:0UGB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―